Journal of cardiology最新文献

{"title":"Association between complementary use of Goreisan (a Japanese herbal Kampo medicine) and heart failure readmission: A nationwide propensity score-matched study","authors":"Toshiaki Isogai MD, MPH ,&nbsp;Kojiro Morita PhD, MPH, RN, PHN ,&nbsp;Akira Okada MD, MPH, PhD ,&nbsp;Nobuaki Michihata MD, MPH, PhD ,&nbsp;Hiroki Matsui PhD, MPH ,&nbsp;Atsushi Miyawaki MD, PhD ,&nbsp;Taisuke Jo MD, PhD ,&nbsp;Hideo Yasunaga MD, PhD","doi":"10.1016/j.jjcc.2024.09.010","DOIUrl":"10.1016/j.jjcc.2024.09.010","url":null,"abstract":"<div><h3>Background</h3><div>Goreisan, a Japanese herbal medicine, possesses aquaretic properties to regulate body fluid homeostasis and may therefore be effective as a complement to standard therapy in improving outcomes in patients with heart failure (HF).</div></div><div><h3>Methods</h3><div>We retrospectively identified 431,393 patients (mean age 79.2 ± 12.6 years; male 52.3 %) who were admitted for HF for the first time and were discharged alive with standard HF medications between April 2016 and March 2022, using the Japanese Diagnosis Procedure Combination database. We divided patients into two groups according to the prescription of Goreisan at discharge: patients who received standard HF medications plus Goreisan and those who received standard medications alone. We compared the incidence of HF readmission within 1 year after discharge between the groups using propensity score matching.</div></div><div><h3>Results</h3><div>Overall, Goreisan was prescribed in 1957 (0.45 %) patients at discharge. Patients who received Goreisan were older and received diuretics more frequently than those who did not. One-to-four propensity score matching created a cohort of 1957 and 7828 patients treated with and without Goreisan, respectively. No significant difference was found in the incidence of 1-year HF readmission between the groups [22.1 % vs. 21.7 %; hazard ratio (HR) = 1.02, 95 % confidence interval (CI) = 0.92–1.13]. This result was consistent with that from competing risk analysis (subdistribution HR = 1.02, 95 % CI = 0.92–1.13) and across clinically relevant subgroups except for renal disease. Goreisan use was associated with a lower incidence of HF readmission among patients with renal disease (HR = 0.77, 95 % CI = 0.60–0.97), but not among those without (HR = 1.09, 95 % CI = 0.97–1.23; <em>p</em> for interaction = 0.009).</div></div><div><h3>Conclusions</h3><div>This nationwide propensity score-matched analysis did not demonstrate that complementary Goreisan use at discharge was associated with a lower incidence of 1-year HF readmission in patients with HF receiving standard medications. An ongoing randomized trial is awaited to establish the effectiveness of Goreisan use in patients with HF.</div></div>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"85 3","pages":"Pages 220-228"},"PeriodicalIF":2.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142347435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Usefulness of hypochloremia at the time of discharge to predict prognosis in patients with chronic heart failure after hospitalization","authors":"Kayo Misumi MD, PhD ,&nbsp;Yuya Matsue MD, PhD ,&nbsp;Kazutaka Nogi MD, PhD ,&nbsp;Yudai Fujimoto MD ,&nbsp;Nobuyuki Kagiyama MD, PhD ,&nbsp;Takatoshi Kasai MD, PhD, FJCC ,&nbsp;Takeshi Kitai MD, PhD ,&nbsp;Shogo Oishi MD ,&nbsp;Eiichi Akiyama MD ,&nbsp;Satoshi Suzuki MD, PhD, FJCC ,&nbsp;Masayoshi Yamamoto MD, PhD ,&nbsp;Keisuke Kida MD, PhD, FJCC ,&nbsp;Takahiro Okumura MD, PhD, FJCC ,&nbsp;Maki Nogi MD, PhD ,&nbsp;Satomi Ishihara MD, PhD ,&nbsp;Tomoya Ueda MD, PhD ,&nbsp;Rika Kawakami MD, PhD, FJCC ,&nbsp;Yoshihiko Saito MD, PhD, FJCC ,&nbsp;Tohru Minamino MD, PhD, FJCC","doi":"10.1016/j.jjcc.2024.08.011","DOIUrl":"10.1016/j.jjcc.2024.08.011","url":null,"abstract":"<div><h3>Background</h3><div>Hypochloremia has been suggested as a strong marker of mortality in hospitalized patients with heart failure (HF). This study aimed to clarify whether incorporating hypochloremia into pre-existing prognostic models improved the performance of the models.</div></div><div><h3>Methods</h3><div>We tested the prognostic value of hypochloremia (&lt;97 mEq/L) measured at discharge in hospitalized patients with HF registered in the REALITY-AHF and NARA-HF studies. The primary outcome was 1-year mortality after discharge.</div></div><div><h3>Results</h3><div>Among 2496 patients with HF, 316 (12.6 %) had hypochloremia at the time of discharge, and 387 (15.5 %) deaths were observed within 1 year of discharge. The presence of hypochloremia was strongly associated with higher 1-year mortality compared to those without hypochloremia (log-rank: <em>p</em> &lt; 0.001), and this association remained even after adjustment for the Get With the Guideline–HF risk model (GWTG-HF), anemia, New York Heart Association (NYHA) classification, and log-brain natriuretic peptide (BNP) [hazard ratio (HR) 1.64; <em>p</em> &lt; 0.001]. Furthermore, adding hypochloremia to the prediction model composed of GWTG-HF + anemia + NYHA class + log-BNP yielded a numerically larger area under the curve (0.740 vs 0.749; <em>p</em> = 0.059) and significant improvement in net reclassification (0.159, <em>p</em> = 0.010).</div></div><div><h3>Conclusions</h3><div>Incorporating the presence of hypochloremia at discharge into pre-existing risk prediction models provides incremental prognostic information for hospitalized patients with HF.</div></div>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"85 3","pages":"Pages 235-240"},"PeriodicalIF":2.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142119910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current knowledge about infective endocarditis prevention among dentists affiliated with the Japanese Dental Association.","authors":"Tamami Kadota, Tatsuya Akitomo, Yuko Iwamoto, Rena Okawa, Yusuke Mikasa, Takahiro Ohara, Masao Daimon, Chisato Izumi, Kenichi Yanagita, Ryota Nomura, Kazuhiko Nakano","doi":"10.1016/j.jjcc.2025.02.018","DOIUrl":"10.1016/j.jjcc.2025.02.018","url":null,"abstract":"","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AI-echocardiography: Current status and future direction.","authors":"Yuki Sahashi, David Ouyang, Hiroyuki Okura, Nobuyuki Kagiyama","doi":"10.1016/j.jjcc.2025.02.005","DOIUrl":"https://doi.org/10.1016/j.jjcc.2025.02.005","url":null,"abstract":"<p><p>Echocardiography, which provides detailed evaluations of cardiac structure and pathology, is central to cardiac imaging. Traditionally, the assessment of disease severity, treatment effectiveness, and prognosis prediction relied on detailed parameters obtained by trained sonographers and the expertise of specialists, which can limit access and availability. Recent advancements in deep learning and large-scale computing have enabled the automatic acquisition of parameters in a short time using vast amounts of historical training data. These technologies have been shown to predict the presence of diseases and future cardiovascular events with or without relying on quantitative parameters. Additionally, with the advent of large-scale language models, zero-shot prediction that does not require human labeling and automatic echocardiography report generation are also expected. The field of AI-enhanced echocardiography is poised for further development, with the potential for more widespread use in routine clinical practice. This review discusses the capabilities of deep learning models developed using echocardiography, their limitations, current applications, and research utilizing generative artificial intelligence technologies.</p>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143537207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of glucagon-like peptide-1 receptor agonists in HFpEF and obesity without diabetes mellitus.","authors":"Aravinthan Vignarajah, Jia Yean Thong, Min Choon Tan, Nishanthi Vigneswaramoorthy, Senthil Anand, Justin Z Lee","doi":"10.1016/j.jjcc.2025.02.017","DOIUrl":"10.1016/j.jjcc.2025.02.017","url":null,"abstract":"","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143482947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coronary anomalies in single ventricles: Insights from selective angiographic assessment.","authors":"Yuko Wakisaka, Kei Inai, Gen Harada, Seiji Asagai, Eriko Shimada","doi":"10.1016/j.jjcc.2025.02.009","DOIUrl":"10.1016/j.jjcc.2025.02.009","url":null,"abstract":"<p><strong>Background: </strong>Adults with congenital heart disease have a higher risk of coronary artery disease compared to the general population. However, there is limited information on coronary artery distribution in patients with a single ventricle (SV), which is important in understanding potential cardiovascular events. This study aimed to evaluate coronary artery morphology and anomalies in patients with SV based on selective coronary angiography (CAG).</p><p><strong>Methods: </strong>We performed a retrospective single-center study including 80 patients with SV [median age, 29 years (range 13-50); 54 % males] who underwent selective CAG at our institution between 2019 and 2023. Patients were classified into either single right or left ventricular (SRV and SLV) morphologies and categorized into D-, L-, and X-loops based on the rules of cardiovascular looping. Coronary artery morphology, dominance, and the abnormality of origin were evaluated.</p><p><strong>Results: </strong>Of the 80 SV patients, 56 had SRV and 24 had SLV. Patients with coronary artery looping surrounding the rudimentary chamber were more frequent in cases with D-loops. In patients with SV, right coronary artery dominance was observed in 70 %, and anomalous origins of coronary artery origins were found in 36.3 % of cases, with a higher frequency of L-loops. Overall, cardiovascular events were observed in patients with SV as follows: 46 % of patients had arrhythmias, 13 % had heart failure, and 8 % had thrombosis; there were no cardiovascular deaths. A single coronary artery was identified in 9 cases (11 %) of SV patients, exclusively in SRV, of which 2 cases (22 %) had arrhythmias and 1 case (11 %) had thrombus.</p><p><strong>Conclusion: </strong>Selective CAG revealed a high prevalence of coronary artery anomalies in patients with SV, emphasizing the importance of comprehensive assessment and long-term follow-up to manage cardiovascular risk in this patient population.</p>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143449132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Author's reply to \"How to indicate left atrial posterior wall isolation adjunctive to conventional pulmonary vein isolation in patients with atrial fibrillation\".","authors":"Zheng-Qi Song, Xin-Yu Lu, Yu-Peng Xu, Hui Lin, Yi-He Chen","doi":"10.1016/j.jjcc.2025.02.015","DOIUrl":"10.1016/j.jjcc.2025.02.015","url":null,"abstract":"","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143433234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TRP channels in cardiac mechano-redox coupling and diseases.","authors":"Xinya Mi, Di Wu, Tomoya Ito, Yuri Kato, Akiyuki Nishimura, Motohiro Nishida","doi":"10.1016/j.jjcc.2025.02.016","DOIUrl":"10.1016/j.jjcc.2025.02.016","url":null,"abstract":"<p><p>Reactive oxygen species (ROS) produced by mechanically stretching cardiomyocytes is a crucial mediator to increase contractile force in accordance with the Frank-Starling law. However, excessive ROS production leads to oxidative stress, contributing to myocardial atrophic remodeling and cellular damage. NADPH oxidase, the primary enzyme responsible for ROS production localized on the plasma membrane and organelle membranes, plays a key role in membrane-oriented ROS signaling. Two isoforms of NADPH oxidase, Nox2 (constitutive) and Nox4 (inducible), are predominantly expressed in cardiomyocytes, each playing unique roles in different contexts. Recent studies have revealed that Nox proteins form protein signaling complexes with transient receptor potential (TRP) channel proteins, amplifying ROS signaling in hearts. This review presents the putative mechanism of protein-protein interaction between TRP and Nox and their pathophysiological significance in hearts and discusses therapeutic strategies targeting TRP-Nox protein interactions for the treatment of heart failure.</p>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic values of atrial high-rate episodes on mortality risks in CIED patients.","authors":"Phuuwadith Wattanachayakul, Panat Yanpiset, Narathorn Kulthamrongsri, Vitchapong Prasitsumrit, Kevin Bryan Lo, Jakrin Kewcharoen, Sumeet Mainigi","doi":"10.1016/j.jjcc.2025.02.010","DOIUrl":"10.1016/j.jjcc.2025.02.010","url":null,"abstract":"<p><strong>Background: </strong>Recent data showed that patients with cardiac implantable electronic devices (CIEDs) who have atrial high-rate episodes (AHRE) have an increased risk of systemic thromboembolism even without a history of atrial fibrillation. However, data regarding the impact of AHRE on mortality outcomes remain conflicting. This study aims to elucidate this relationship by summarizing all available data via systematic review and meta-analysis.</p><p><strong>Methods: </strong>We systematically reviewed MEDLINE and EMBASE from inception to May 2024 to evaluate the association between AHRE and mortality risk in patients with CIED who did not have a history of atrial fibrillation at implantation. We compared all-cause and cardiovascular mortality in patients with AHRE to those without AHRE. Relative risk (RR) or hazard ratio and their 95 % confidence intervals (CIs) were extracted from each study and combined using the generic inverse variance method.</p><p><strong>Results: </strong>A total of 15 cohort studies were included in the meta-analysis. The pooled analysis showed that patients with AHRE had a higher risk of all-cause mortality compared to those without AHRE, with a pooled RR of 1.57 (95 % CI 1.21-2.03; I² = 67 %; p < 0.001). Similarly, AHRE was associated with higher cardiovascular mortality, with a pooled RR of 1.80 (95 % CI 1.06-3.05; I² = 49 %; p = 0.03).</p><p><strong>Conclusions: </strong>Our study found that patients with CIEDs who developed AHRE were at a higher risk of all-cause and cardiovascular mortality compared to those without AHRE.</p>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implications of asymptomatic hypotension for patients prescribed sacubitril/valsartan: Insight from the REVIEW-HF registry.","authors":"Wataru Fujimoto, Shingo Matsumoto, Koshiro Kanaoka, Takahito Nasu, Keisuke Kida, Nobuyuki Kagiyama, Shunsuke Ishii, Yukihiro Watanabe, Atsushi Kikuchi, Takeshi Ijichi, Tatsuhiro Shibata, Hidekazu Tanaka","doi":"10.1016/j.jjcc.2025.02.012","DOIUrl":"10.1016/j.jjcc.2025.02.012","url":null,"abstract":"<p><strong>Background: </strong>Sacubitril/valsartan has unequivocally demonstrated prognostic improvement in patients with chronic heart failure in large-scale randomized controlled trials. However, it remains uncertain whether patients presenting with asymptomatic hypotension have distinct prognoses compared to those with symptomatic hypotension, and there is no consensus on the optimal strategy for managing asymptomatic hypotension.</p><p><strong>Methods and results: </strong>A multicenter retrospective study was conducted, analyzing data from patients initiated on sacubitril/valsartan therapy. The primary outcome was a composite of cardiovascular death or a hospitalization for heart failure. Among 992 patients, 72 patients (7.3 %) experienced symptomatic hypotension, and 122 patients (12.3 %) experienced asymptomatic hypotension within three months. The incidence of primary endpoint for patients who experienced hypotension, regardless of whether it was symptomatic or asymptomatic, was higher than for those who did not experience hypotension (Log-rank p < 0.05). Among patients who experienced asymptomatic hypotension, 23 patients discontinued sacubitril/valsartan within three days after the onset of asymptomatic hypotension. Patients who discontinued sacubitril/valsartan after the occurrence of asymptomatic hypotension experienced a significantly higher incidence of primary endpoints compared to those who continued sacubitril/valsartan therapy (Log-rank p = 0.01).</p><p><strong>Conclusion: </strong>The prognosis of patients who discontinued sacubitril/valsartan after the occurrence of asymptomatic hypotension during sacubitril/valsartan therapy was poor. It may be beneficial to aim for the continuation of sacubitril/valsartan therapy even after the occurrence of asymptomatic hypotension.</p>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}